The MD Magazine Multiple Sclerosis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
Ocrelizumab Delays Wheelchair Need by 7 Years for Patients with Progressive MS
From Phase 1 to FDA Approval: Following a Drug Through the Development Pipeline
FDA Approves First Multiple Sclerosis Therapy for Children
Teriflunomide Therapy Switch Improves Patient Satisfaction in Relapsing MS
AAN Emphasizes Patient Perspective, Transparency in MS Guideline Development
New MS Guideline Addresses Starting, Switching, and Stopping Disease-modifying Therapy
Ocrelizumab Succeeds in Open-label Extension of OPERA Trials
Latino Patients with MS Struggle with Depression, Fewer Resources
Siponimod Reduces Disability Progression, Cognitive Effects of SPMS
Are Some Risk Factors for Multiple Sclerosis Avoidable?
Next Page >>
Choosing Among Antidiabetes Agents
Empathy from Physicians More Likely to Result in Patient Information from Family
Characterizing Dangerous, Unregulated Stem Cell Therapy for Ocular Disease
CANTREAT Results Show Treat-and-Extend Benefits Versus Once-Monthly for AMD
Real-World Analysis Supports More Frequent Anti-VEGF Dosing for First-Year nAMD
Affordable Care Act
PHYSICIAN'S MONEY DIGEST >
MD Magazine Resources
Terms & Conditions
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.